Springer Nature OA
open access
Manufacturing, GMP, Regulatory, and Commercialization Pathways
This chapter addresses manufacturing, regulatory, and commercialization pathways for MSC–EV-based therapeutics. It discusses GMP-compliant production, process scalability, and comparability challenges. Regulatory frameworks from major agencies are analyzed, with emphasis on potency assays, quality c
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Towards a greener pharmaceuticals' regulatory highway#416978
- Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products; Draft Guidance for Industry; Availability; Comment Request#512201
- Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks#163561
- The Collective Action of Firms on Regulatory Science: Mechanistic Toxicology as a Market‐Making Epistemic Strategy in the R&D Agrochemical Industry#983984
- Emerging Biotechnologies in Europe: Foresight for Policy#271042
Record · ID 1317923
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive